Psyence Biomedical Ltd. Names New Head of Clinical Development
Ticker: PBMWW · Form: 6-K · Filed: Oct 9, 2025 · CIK: 1985062
Sentiment: neutral
Topics: leadership-change, clinical-development, biotech
TL;DR
Psyence Biomedical Ltd. CEO Neil Maresky steps down to lead global clinical development.
AI Summary
Psyence Biomedical Ltd. announced on October 9, 2025, that Dr. Neil Maresky has transitioned from CEO and Director to Global Head of Clinical Development. In his new role, he will lead the company's global clinical development initiatives, including its pharmaceutical programs.
Why It Matters
This leadership change signals a strategic shift for Psyence Biomedical Ltd., focusing on the expansion and execution of its global clinical development pipeline.
Risk Assessment
Risk Level: low — This filing is a routine leadership transition announcement and does not involve financial distress or significant operational changes.
Key Players & Entities
- Psyence Biomedical Ltd. (company) — The company making the announcement.
- Dr. Neil Maresky (person) — Transitioning from CEO and Director to Global Head, Clinical Development.
FAQ
What is the effective date of Dr. Neil Maresky's transition?
The filing does not specify an exact effective date for Dr. Maresky's transition, but it is announced in the report for the month of October 2025.
What will be Dr. Maresky's primary responsibilities in his new role?
Dr. Maresky will lead Psyence Biomedical Ltd.'s global clinical development initiatives, including its pharmaceutical programs.
What was Dr. Maresky's previous role at Psyence Biomedical Ltd.?
Dr. Maresky previously served as the Chief Executive Officer and Director of Psyence Biomedical Ltd.
What type of filing is this report?
This is a Form 6-K report, which is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Where is Psyence Biomedical Ltd. headquartered?
Psyence Biomedical Ltd. is located at 121 Richmond Street West Penthouse Suite 1300, Toronto, Ontario, M5H 2K1.
Filing Stats: 307 words · 1 min read · ~1 pages · Grade level 13.6 · Accepted 2025-10-09 16:17:25
Filing Documents
- ea0260790-6k_psyence.htm (6-K) — 15KB
- 0001213900-25-097819.txt ( ) — 16KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025 Commission File Number: 001-41937 Psyence Biomedical Ltd. (Translation of registrant’s name into English) 121 Richmond Street West Penthouse Suite 1300 Toronto, Ontario M5H 2K1 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Explanatory Note Psyence Biomedical Ltd (the “Company”) announced that Dr. Neil Maresky has transitioned from his role as Chief Executive Officer and Director of Psyence Biomedical Ltd. to serve as the Company’s Global Head, Clinical Development, where he will lead the Company’s global clinical development initiatives, including its Phase 2b clinical trial in Australia. In connection with this transition, the Company’s Chairman, Mr. Jody Aufrichtig, has assumed the role of Chief Executive Officer and will oversee Nasdaq-related and corporate operations. The vacancy on the Board resulting from Dr. Maresky’s transition will be filled either by way of a vote of a quorum of Directors or at the Company’s next annual general meeting of shareholders, in accordance with applicable law and the Company’s governing documents. Incorporation by Reference The information contained in this Report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-285542), and any prospectuses or prospectus supplements filed pursuant thereto. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: October 9, 2025 Psyence Biomedical Ltd. By: /s/ Warwick Corden-Lloyd Name: Warwick Corden-Lloyd Title: Chief Financial Officer 2